Table 1 Characteristics of the patients
Characteristics | Azvudine (n = 14) | Nirmatrelvir/ritonavir (n = 18) | SOC (n = 23) |
|---|---|---|---|
Age (years), mean ± SD | 82.9 ± 2.81 | 84.2 ± 4.12 | 85.5 ± 4.40 |
Sex (male), n (%) | 6 (42.9%) | 5 (27.8%) | 9 (39.1%) |
Severity at admission, n (%) | |||
Mild | 1 (7.1%) | 3 (16.7%) | 21 (91.3%) |
Moderate | 13 (92.9%) | 15 (83.3%) | 2 (8.7%) |
COVID-19 vaccine (≥ 1 dose), n (%) | 4 (28.6%) | 8 (44.4%) | 11 (47.8%) |
Underlying diseases, n (%) | 9 (64.3%) | 13 (72.2%) | 16 (69.6%) |
Number of symptoms, median (range) | 1 (0–4) | 1 (0–5) | 2 (1–4) |
Ct value, median (range) | 21.3 (18.9–34.5) | 21.3 (14.9–32.3) | 22.1 (15.2–34.3) |
Missing, n (%) | 3 (21.4%) | 3 (16.7%) | 1 (4.3%) |